Eiger Biopharmaceuticals Inc (EIGRQ)
OTCMKTS: EIGRQ · Delayed Price · USD
3.040
0.00 (0.00%)
Apr 25, 2024, 12:00 AM EDT - Market open
Eiger Biopharmaceuticals Revenue
In the year 2023, Eiger Biopharmaceuticals had annual revenue of $15.77M with 16.98% growth. Revenue in the quarter ending December 31, 2023 was $3.80M with 41.06% year-over-year growth.
Revenue (ttm)
$15.77M
Revenue Growth
+16.98%
P/S Ratio
0.16
Revenue / Employee
$281,661
Employees
56
Market Cap
2.55M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.77M | 2.29M | 16.98% |
Dec 31, 2022 | 13.48M | 1.34M | 11.05% |
Dec 31, 2021 | 12.14M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Jun 30, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
EIGRQ News
- 4 weeks ago - Healthcare stocks fade as obesity-drug optimism fades - Market Watch
- 4 weeks ago - Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection - GlobeNewsWire
- 3 months ago - Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan - PRNewsWire
- 4 months ago - Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split - PRNewsWire
- 6 months ago - Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - PRNewsWire
- 8 months ago - Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta - PRNewsWire
- 8 months ago - Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference - PRNewsWire
- 9 months ago - Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - PRNewsWire